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ABSTRACT
Purpose
Reports investigating whether the response rates to
palliative radiation therapy (RT) for painful bone
metastases from gastrointestinal (GI) cancers are simi-
lar to rates for bone metastases from other primary
cancer sites have been limited. The present study evalu-
ated response rates for symptomatic bone metastases
from GI cancers after palliative outpatient RT in the
Rapid Response Radiotherapy Program (RRRP).
Patients and Methods
We identified 69 patients with bone metastases from
GI primaries who received palliative RT in the RRRP
clinic during 1999–2006. We extracted records for 31
of these patients during 1999–2003 from an RRRP data-
base that used the Edmonton Symptom Assessment
Scale (ESAS). Record for the remaining 38 patients
during 2003–2006 were extracted from an RRRP data-
base that used the Brief Pain Inventory (BPI). Eligibil-
ity criteria for encryption in the two RRRP databases
and for collection of patient demographic information
(age, sex, primary cancer site, and Karnofsky perform-
ance status) were identical.
Response rates for this cohort of metastatic GI pa-
tients were then compared to rates for 479 patients re-
ceiving palliative RT for bone metastases from other
primary cancer sites. Pain scores from the ESAS and
BPI and data on analgesic consumption were collected
at baseline and by telephone follow-up at 4, 8, and 12
weeks after RT for all patients. Complete (CR), partial
(PR), and overall (CR+PR) responses were evaluated
according to International Consensus Endpoints.
Results
Assessment of the 69 patients with metastatic GI can-
cers revealed CR, PR, and CR+PR rates of 18%, 42%,
and 61% at 4 weeks; 22%, 35%, and 57% at 8 weeks;
and 50%, 21%, and 71% at 12 weeks for evaluable
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patients. The 479 evaluable patients with metastatic
cancer from other primary cancer sites had CR, PR,
and CR+PR rates of 25%, 27%, and 51% at 4 weeks;
26%, 22%, and 48% at 8 weeks; and 22%, 29%, and
51% at 12 weeks. No statistically significant differ-
ences were observed in RT response rates for bone
metastases from GI cancers than from other primary
cancer sites.
Conclusions
After palliative RT, bone metastases from GI cancers
demonstrate response rates that are similar to rates for
metastases from other primary cancer sites. Patients
with symptomatic bone metastases from GI malignan-
cies should be referred for palliative RT as readily as
patients with osseous metastases from other primary
cancer sites.
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1. INTRODUCTION
Bone metastases are a common complication of can-
cer. Bone is the third most common site of metastasis
after lung and liver 1. Secondary bone tumours are par-
ticularly common in breast (47%–85%), prostate (54%–
85%), lung (32%–40%), thyroid (28%–60%), and renal
cell (33%–40%) cancers 1. Bone pain is the most com-
mon secondary symptom, with 50%–75% of individu-
als experiencing severe pain at some point during the
course of their disease 2. As a result of severe pain, a
patient’s quality of life, personal relationships, and psy-
chological well-being can be significantly impaired.
Palliative radiotherapy (RT) is an effective means of
pain and symptom management for advanced cancer
patients with bone metastases 3. Specifically, reports
indicate that up to 90% of patients experience pain re-
lief following palliative RT to symptomatic osseous
metastases 3.DFHGI BONE METASTASES: RT RESPONSE
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Randomized clinical trials have been conducted to
determine the optimal dose fractionation for sympto-
matic relief of painful bony metastases. Multiple
randomized controlled trials and three recent well-con-
ducted meta-analyses concluded that pain relief is not
significantly different with single-fraction or multiple-
fraction palliative RT 4–6.
The development of skeletal metastases originat-
ing from gastrointestinal (GI) cancers is an uncommon
event and typically presents in very advanced cases.
The incidence of bone metastases in colorectal car-
cinomas ranges from 5.6% to 7.9% 7,8. Traditionally,
the incidence of bone metastases from hepatocellu-
lar carcinoma (HCC) has been reported to be low (0%–
5%) 9,10, but more recent investigations have reported
an incidence of 6%–20% 11,12. Similarly, bone
metastases from pancreatic carcinoma are becoming
more common 13. Improvements in the diagnosis and
treatment of these cancers have been credited for the
observed increase in osseous metastasis 12,13. With this
trend comes an immediate need for effective and timely
symptomatic management within this cohort.
Most trials documenting RT response rates for bone
metastases have accrued patients with breast, pros-
tate, and lung primary cancers 4–6. Furthermore, bone
metastases from breast and prostate cancers are typi-
cally considered highly radiosensitive 14 and therefore
frequently responsive to a palliative RT intervention.
Although no a priori reason exists to expect a different
result for GI primary malignancies, the literature con-
tains only limited reports concerning response rates
for bone metastases from GI primaries after pallia-
tive RT 4–6. The present study examined response rates
after palliative RT for the treatment of bone metastases
from GI cancers to determine if response rates are sig-
nificantly different from rates seen with RT of metastases
from other primary cancer sites.
2. PATIENTS AND METHODS
The Rapid Response Radiotherapy Program (RRRP) at
the Odette Cancer Centre developed a database for
outpatients referred for palliative RT for bone
metastases. The RRRP is an outpatient clinic that has
been providing timely access to palliative RT since its
start as a pilot program in 1996. Patients with advanced
incurable cancer are referred to the RRRP for rapid
access to palliative RT to relieve suffering and to im-
prove quality of life 15. More than 60% of patients seen
in the RRRP are referred for bone metastases 16.
We identified 69 patients with bone metastases
from GI primaries who received palliative RT in the
RRRP clinic. We extracted records for 31 of these pa-
tients who were seen during 1999–2003 from an RRRP
database that used the Edmonton Symptom Assessment
Scale (ESAS). We extracted the remaining 38 patients
who were seen during 2003–2006 from an RRRP data-
base that used the Brief Pain Inventory (BPI). Eligibility
criteria for encryption in both RRRP databases (the 1999–
2003 version and the 2003–2006 version) were identi-
cal. Both study databases collected patient demographics
[age, sex, primary cancer site, and Karnofsky perform-
ance status (KPS)], site of RT, delivered RT dose, pain
score (0–10), and oral morphine equivalent dose
(OMED). Merging the two sets of data for the study
was therefore possible.
The research assistant approached all eligible pa-
tients seen in the RRRP. No preference was made re-
garding patients with a metastatic GI cancer diagnosis.
We observed no statistically significant differences in
age, sex, primary cancer site, or KPS between the two
GI cohorts (that is, the 31 patients accrued from 1999–
2003 and the 38 patients accrued from 2003–2006; data
not shown).
Ethics approval to conduct the analysis was ob-
tained from the Sunnybrook Health Sciences Centre
Research Ethics Board. Study participants provided
written consent at the baseline assessment. Eligible
patients had to be English-speaking and able to com-
plete the symptom assessment, and had to have a pre-
viously demonstrated histologically or cytologically
proven primary cancer site. All malignant histologies
or cytologies were eligible. The presence of bone
metastases corresponding to clinically painful areas had
to have been confirmed by nuclear bone scan, com-
puted tomography, or magnetic resonance imaging.
Patients were excluded from the study if a current
or impending fracture was observed at the radiated site,
or if a spinal cord compression (CC) existed at the time
of enrolment into the study. Because radiologic evi-
dence of bone metastases was required for eligibility
for the trial, pathologic fracture, impending fracture,
and spinal CC were identified according to the corre-
sponding radiology report. Patients considered at “high
risk for fracture” were not included in the investiga-
tion. Patients undergoing re-treatment were also ineli-
gible for the study.
Using the ESAS and BPI questionnaires, participants
were asked to rate their pain intensity on a categorical
scale of 0 to 10 (0 indicating absence of pain; 10 indi-
cating worst pain possible). Patient demographics and
information on disease extent were collected at the
baseline interview. Analgesic intake during the preced-
ing 24 hours was recorded and converted into an OMED.
Because the BPI “worst pain” score has been shown
to correlate most significantly with functional inter-
ference 17–23, we used this value to evaluate response
to RT.
The research assistant conducted follow-ups at 1,
2, and 3 months (weeks 4, 8, and 12) post treatment.
The follow-up interviews, conducted over the telephone
or in person if the patient was scheduled for an ap-
pointment at the cancer centre, inquired about pain level
and analgesic consumption.
Response rates were determined according to the
International Consensus Endpoints 24 at 4, 8, and 12
weeks. “Complete response” (CR) was defined as a
pain score of 0 at the treated site with no concomitantHIRD et al.
CURRENT ONCOLOGY—VOLUME 15, NUMBER 5
221 221 221 221 221
increase in analgesic intake (stable or reduced analge-
sics in daily OMEDs). “Partial response” (PR) was de-
fined as
￿ a reduction in pain score of 2 or more points at the
treated site on a scale of 0 to 10 without analgesic
increase, or
￿ a reduction in analgesic use of 25% or more from
baseline without an increase in pain.
Overall response (CR+PR) was calculated by add-
ing the proportion of complete responders to the pro-
portion of partial responders.
2.1 Statistical Methods
Descriptive statistics were recorded as percentages for
proportions and as medians and ranges for parametric
values. All statistical analyses were performed using
the Statistical Analysis System (SAS: SAS Institute,
Cary, NC, U.S.A.). To evaluate RT response rates, we
used a confidence interval of 95%, and we considered
p values below 0.05 to be statistically significant.
3. RESULTS
For the period 1999–2003, we enrolled a total of 518
patients 25. Within this study population, we identified
31 patients whose bone metastases had GI cancer pri-
maries. An additional 38 patients with bone metastases
from GI cancers were extracted from the database span-
ning 2003–2006. Thus, we analyzed an overall sample
of 69 GI metastatic patients. Table I shows the base-
line patient demographics for this cohort, which con-
tained 48 men (70%) and 21 women (30%). Median
age of the cohort was 68 years (range: 37–89 years),
and they had a median KPS score of 60 (range: 40–90).
The most common GI primary cancer sites were
colorectal (68%), pancreatic (16%), and gastric (9%).
The most prevalent dose fractionations were a single
fraction of 8 Gy (49%) and 20 Gy in 5 fractions (44%).
Table II lists the sites of radiation. Median baseline
pain score at the irradiated site was 6 (range: 0–10).
The mean and median OMEDs were 134 mg and 60 mg
respectively (range: 0–1584 mg).
Removing the GI patients from the initial cohort of
518 patients produced a group of 479 patients with bone
metastases from other primary cancer sites (Table III).
This cohort was used for comparison of palliative RT
response rates. It contained 253 men (53%) and 226
women (47%), whose median age was 69 years (range:
31–93 years). These patients presented with a median
KPS of 60 (range: 10–100). Most patients had primary
lung (27%), breast (26%), or prostate (24%) cancer.
Table IV lists the RT sites for this cohort. Median base-
line pain score at the irradiated site was 6 (range: 0–
10). The mean and median OMEDs were 101 mg and
30 mg respectively (range: 0–3600 mg). Patients were
typically treated with a linear accelerator or a cobalt
machine. Parallel-opposed fields were used to treat
pelvis, limbs, and cranium; a direct oppositional field
was used for the thoracic cage and spine. Follow-up
assessments using the ESAS and BPI were conducted
over the telephone or in person if the patient had been
scheduled to return to the clinic for a follow-up with
the clinician.
The numbers of GI patients who successfully com-
pleted follow-up assessments at 4, 8, and 12 weeks
after RT were 33 (48%), 23 (33%), and 14 (28%) re-
spectively. Table V shows response rates determined
according to the International Consensus Endpoints 24.
For evaluable patients, the CR, PR, and overall (CR+PR)
rates were 18%, 42%, and 61% at 4 weeks; 22%, 35%,
and 57% at 8 weeks; and 50%, 21%, and 71% at 12
weeks after RT.
For the cohort of 479 patients with bone metastases
from other (that is, non-GI) primary cancer sites, the
TABLE I Characteristics of patients (n = 69) receiving palliative ra-
diotherapy (RT) to symptomatic bone metastases originating from
gastrointestinal cancers
                      Characteristic Value
Sex [n (%)]
Male 48 (70)
Female 21 (30)
Age at RT (years)
Median 68
Range 37–89
Worst pain
Median 6
Range 0–10
Oral morphine equivalent dose (mg)
Mean 134±229
Median 60
Range 0–1584
Primary cancer site [n (%)]
Colorectal 47 (68)
Pancreatic 11 (16)
Stomach 6 (9)
Esophageal 3 (4)
Liver 2 (3)
Karnofsky performance status at first visit
Median 60
Range 40–90
Dose fractionation [n (%)]
8 Gy in 1 fraction 34 (49)
20 Gy in 5 fractions 30 (44)
Others 5 (7)
TABLE II Sites of radiation for gastrointestinal cancer patients (n = 69)
Radiation site n (%)
Spine 22 (32)
Pelvis 18 (26)
Extremities 13 (19)
Rib cage 5 (7)
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(Table V). These results suggest that bone metastases
from GI cancers respond to palliative RT as well as do
metastases from other primary cancer sites.
4. DISCUSSION
Many randomized trials and three recent meta-analy-
ses of dose-fractionation RT for the palliation of pain-
ful bone metastases have concluded that single and
multiple fractionations are equivalent 4–6. We there-
fore combined the various dose fractionation sched-
ules to assess the response rates of the entire cohort.
The response rate to RT is a function of endpoint.
The International Consensus Endpoints take into ac-
count both pain score and analgesic consumption 24.
This method of evaluation lowers the CR and PR rates
as compared with the pain-only endpoints. Moreover,
as compared with analyzing pain score alone, using
this method to calculate overall response produces a
more accurate reflection of the true efficacy of RT.
We integrated the International Consensus Endpoints
into our analysis to promote consistency and to facili-
tate comparisons across trials. As predicted, the re-
sponse rates reported in the present analysis are lower
than the rates traditionally reported.
Literature on the effectiveness of palliative RT for
bone metastases from GI cancers is limited 11,26–34.
Large randomized controlled trials have not addressed
response rates for GI bone metastases specifically. To
our knowledge, no study directed at detecting differ-
ences in RT response rates between bone metastases
from GI malignancies and those from other primary
cancer sites has been conducted. Discrepancies re-
garding the perceived radiosensitivity of GI metastases
may discourage the use of RT. The lengthened prog-
nosis of GI cancer patients, coupled with the increased
incidence of bone metastases from selected GI can-
cers 11–13, creates an immediate need to maximize
pain palliation and symptom management for this
population.
We identified seven studies evaluating response
rates for RT in the treatment of bone metastases from
HCC 28–34. Additionally, we found a single study that
investigated RT response in patients with spinal
metastases from HCC 11; however, the objective of treat-
ment in this latter study was an existing or impending
spinal CC. Given that spinal CC was indicated as an
ineligibility criterion in the current study and in the ref-
erenced randomized clinical trials 4–6,25, we therefore
omitted the results of the aforementioned study from
our comparison.
Each study that evaluated the efficacy of pallia-
tive RT in the treatment of symptomatic bone
metastases from HCC concluded that pain relief was
equal to that previously reported in other more general
trials 28–34. Within the metastatic HCC trials, sample
sizes ranged from 12 to 57 evaluable patients, who were
treated with a range of 12.5 Gy to 65 Gy. Reported
response rates ranged from 73% to 94%.
TABLE IV  Sites of radiation for non-gastrointestinal cancer patients
(n = 486a)
Radiation site n (%)
Spine 140 (29)
Pelvis 150 (31)
Extremities 100 (21)
Rib cage 27 (6)
Other 69 (14)
a  The overall (that is, non-gastrointestinal) patient population
consisted of 479 individuals. However, some patients received
palliative radiation treatment to more than one site of bony me-
tastasis. Therefore, 486 metastatic sites in total were irradiated.
TABLE III  Characteristics of patients (n = 479) receiving palliative
radiotherapy (RT) to symptomatic bone metastases originating from
other (that is, non-gastrointestinal) primary cancers
                   Characteristic Value
Sex [n (%)]
Male 253 (53)
Female 226 (47)
Age at RT (years)
Median 69
Range 31–93
Worst pain
Median 6
Range 0–10
Oral morphine equivalent dose (mg)
Mean 101±239
Median 30
Range 0–3600
Primary cancer site [n (%)]
Lung 131 (27)
Breast 127 (26)
Prostate 117 (24)
Unknown 33 (7)
Multiple myeloma 29 (6.)
Renal cell/kidney 17 (4)
Bladder 11 (2)
Other 14 (3)
Karnofsky performance status at first visit
Median 60
Range 10–100
Dose fractionation [n (%)]
8 Gy in 1 fraction 193 (40)
20 Gy in 5 fractions 199 (42)
Others 87 (18)
CR, PR, and CR+PR rates at 4 weeks after palliative RT
were 25%, 27%, and 51% respectively. For evaluable
patients at the 8-week follow-up, the rates were 26%,
22%, and 48%; and at 12 weeks, they were 22%, 29%,
and 51%.
Using the Fisher exact test, we performed a com-
parison of the response rates for the two cohorts. Given
a 95% confidence interval, we observed no statistically
significant difference in terms of CR, PR, and CR+PRHIRD et al.
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We identified a single study investigating the RT
sensitivity of bone metastases from pancreatic can-
cer 28. Harada et al. evaluated 13 pancreatic cancer
patients with 18 total sites of osseous metastasis. Pain
relief was achieved in 12 of 13 patients (92%) with RT
dosages ranging from 20 Gy to 30 Gy.
Two publications identified RT as an effective thera-
peutic tool in the management of bone pain for skeletal
metastases originating from a colorectal primary 26,27.
Both investigations were retrospective reviews that sum-
marized all colorectal carcinoma cases seen in the
respective clinics. For 1970–1995, Kanthan et al. iden-
tified 5352 cases of colorectal carcinoma, 355 of which
were identified to have osseous metastases 27. A high
preponderance (83.1%) had skeletal metastases in com-
bination with metastases to lung, liver, or brain. The
management of such metastases was palliative in na-
ture. The authors identified RT as the most effective
treatment for pain and adverse symptom control.
Similarly, for the period 1970–1980, Bonnheim et
al. evaluated 1406 patients with primary colorectal
adenocarcinoma 28. In their cohort, 66 patients had
skeletal metastases, and 71% had bone metastases in
combination with other distant metastases. Again, the
most effective treatment for palliation of the bone
metastases was RT.
Our results compare favourably with the trial re-
sults 25–34 and suggest no difference in effectiveness
of RT for the symptomatic relief of pain originating
from metastatic GI cancers to bone. Nonetheless, care
should be used in the interpretation. Although the GI
cancers in our patient population originated mainly from
colorectal, pancreatic, and gastric primaries, published
data on RT response in these malignancies are limited.
As outlined, most of the published data reflect response
in HCC metastases, and only a small proportion of our
study population fell into this category.
Furthermore, inconsistent demographic factors
(that is, age, performance status, and geographic loca-
tion) and treatment-related factors (that is, RT dose)
limit the comparison possibilities between the GI trials
and the present investigation 25–34. The dosing sched-
ules used in the trials varied considerably. Known dos-
ing schedules in the HCC trials ranged from 12.5 Gy to
65 Gy 28–34, and Harada and colleagues delivered a
median dose of 30 Gy to the 13 enrolled metastatic
pancreatic cancer patients 28. Within our study, 8 Gy in
1 fraction or 20 Gy over 5 fractions were the schedules
most often used.
In addition, the absence of universal definitions
of RT response makes comparison between investi-
gations difficult. This difficulty has been documented
not only in the present investigation, but also in exist-
ing publications evaluating the efficacy of palliative
RT 24,26. A concise set of evidence-based endpoints
has to be established to facilitate a comprehensive
evaluation of pain relief following palliative RT in fu-
ture clinical trials.
Our study population consisted only of outpatients
receiving palliative RT in the RRRP clinic who met the
study inclusion criteria; our sample is therefore not
representative of all metastatic cancer patients receiv-
ing RT for bone metastases. A responder bias related to
effect is therefore possible: patients who were avail-
able and willing to complete the follow-up assessment
may have been those who responded favourably to the
RT. Furthermore, the high drop-out rate is a limitation
in the current study. Approximately half of the GI pa-
tients did not complete the 4-week follow-up assess-
ment. The proportion of incomplete assessments further
increased at 8 and 12 weeks after RT. Such a significant
decline in available follow-up data creates a lack of
power within the study. For example, in our trial, the
TABLE V   Comparison, by Fisher exact test at weeks 4, 8, and 12, of evaluable and non-evaluable response ratesa in bone metastases patients,
479 with metastases from non-gastrointestinal primaries and 69 with metastases from gastrointestinal (GI) primaries
Non-GI primary cancer (n=479)  GI primary cancer (n=69) p
Patients Evaluable Non-evaluable Patients Evaluable Non-evaluable Value
(n) [% (95% CI)] [% (95% CI)] (n) [% (95% CI)] [% (95% CI)]
Week 4           [n=251 (52%)]          [n=33 (48%)]
CR 62 25 (19–31) 13 (10–16) 6 18 (7–35) 9 (3–18) 0.52
PR 67 27 (21–33) 14 (11–17) 14 42 (25–61) 20 (12–32) 0.07
CR+PR 129 51 (45–58) 27 (23–31) 20 61 (42–77) 29 (19–41) 0.36
Week 8            [n=219 (46%)]             [n=23 (33%)]
CR 57 26 (20–32) 12 (9–15) 5 22 (7–44) 7 (2–16) 0.80
PR 48 22 (17–28) 10 (7–13) 8 35 (16–57) 12 (5–22) 0.19
CR+PR 105 48 (41–55) 22 (18–26) 13 57 (34–77) 19 (10–30) 0.51
Week 12            [n=188 (75%)]          [n=14 (20%)]
CR 42 22 (17–29) 9 (6–12) 7 50 (23–77) 10 (4–20) 0.05
PR 54 29 (22–36) 11 (9–14) 3 21 (5–51) 4 (1–12) 0.76
CR+PR 96 51 (44–58) 20 (17–24) 10 71 (42–92) 15 (7–25) 0.17
a Response rates were calculated according to the proportion of evaluable (that is, the number of patients contacted at the respective follow-
up assessment) to non-evaluable (that is, total number of) patients in the cohort.
CI = confidence interval; CR = complete response; PR = partial response; CR+PR = overall response.DFHGI BONE METASTASES: RT RESPONSE
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71% response rate for GI patients at week 12 is re-
ported as being not significantly different from the 51%
response rate for patients with other primary cancer
sites. Although a 20% difference in response is large,
a limited sample size created limited power to detect
statistical significance.
Nonetheless, our series is one of the largest re-
porting on radiosensitivity of bone metastases from GI
malignancies. From our analysis, pain relief resulting
from RT in this group of patients is no different from
the relief achieved with RT for metastases from all
other primary sites. Although our data demonstrate lim-
ited power because of the small sample size and high
drop-out rate, we hope our investigation will spark fur-
ther research in the palliative field regarding the radio-
sensitivity of metastatic GI malignancies. Such research
is becoming progressively more significant as the prog-
nosis of GI patients improves, and the incidence of skel-
etal metastases from these cancers increases. In the
meantime, we encourage practitioners to refer GI can-
cer patients with symptomatic bone metastases to pal-
liative RT as readily as they do breast or prostate cancer
patients with bone metastases.
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